Focused On-demand Library for E3 ubiquitin-protein ligase RNF170

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q96K19

UPID:
RN170_HUMAN

ALTERNATIVE NAMES:
Putative LAG1-interacting protein; RING finger protein 170; RING-type E3 ubiquitin transferase RNF170

ALTERNATIVE UPACC:
Q96K19; D3DSY6; E9PIL4; Q7Z483; Q86YC0; Q8IXR7; Q8N2B5; Q8N5G9; Q8NG30; Q9H0V6

BACKGROUND:
The E3 ubiquitin-protein ligase RNF170, known for its alternative names such as Putative LAG1-interacting protein and RING-type E3 ubiquitin transferase RNF170, is essential for the stimulus-induced degradation of ITPR1. Its function in ITPR1 turnover in resting cells underscores its importance in cellular signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of E3 ubiquitin-protein ligase RNF170 could open doors to potential therapeutic strategies for treating rare neurodegenerative diseases like Ataxia, sensory, 1, autosomal dominant, and Spastic paraplegia 85, autosomal recessive, by targeting the underlying genetic variants.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.